ArticleLipids in health and disease2025
Imidazole propionate ameliorates lipid metabolism in adipocytes to attenuate high-fat diet-induced obesity via PPAR signaling pathway.
Article in Lipids in health and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Circulating imidazole propionate and coronary heart disease risk: interplay between histidine intake, fiber, and gut microbiome.BMC medicine · 2026Article
- Microbiota-Derived Metabolites in Developmental Programming: Bridging Early-Life Gut Microbiota to Childhood Metabolic Disorders.Current medical science · 2026Review
- Gut microbiota-derived imidazole propionate is associated with obesity.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundObesity is a global health concern linked to metabolic disorders and gut microbiota dysbiosis, particularly under high-fat diet (HFD) conditions. This study explores the role of imidazole propionate (ImP), a histidine-derived microbial metabolite, in regulating lipid metabolism and the development of obesity.
methodsMale C57BL/6 mice were fed either a chow diet or HFD for 15 weeks, followed by plasma metabolomic analysis, which revealed significant downregulation of ImP in obese mice. Functional assays were performed using zebrafish larvae and human adipocytes, with lipid accumulation assessed via Nile Red and Oil Red O staining. Transcriptomic sequencing and KEGG pathway analysis were used to investigate the underlying molecular mechanisms.
resultsImP treatment notably reduced lipid accumulation in both zebrafish larvae and human adipocytes. RNA-seq and protein expression analyses revealed that ImP suppressed peroxisome proliferator-activated receptor (PPAR) pathway key components, such as FABP4, ACSL4, and CEBPα.
conclusionsThese findings demonstrate that ImP attenuates lipid accumulation by inhibiting the PPAR signaling pathway. As a gut microbial metabolite, ImP may offer therapeutic potential in preventing or treating HFD-induced obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.